The global PD1 non-small cell lung cancer treatment market size is expected to surpass an impressive valuation of US$ 26.96 Billion in 2023 and is projected to reach US$ 61 Billion by 2033, growing at a CAGR of 8.51%
The presence of a strong pipeline for NSCLC is projected to propel growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung cancer is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.
High growth is attributed to the growing patient population, expected entry of several drugs, and increasing investment by industry players in the Research and Development (R&D) of NSCLC therapy. The increasing prevalence of NSCLC across the globe owing to increasing air pollution and smoking habits amongst people is likely to propel market growth over the coming years.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 26.96 Billion |
| Anticipated Forecast Value (2033) | US$ 61 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 8.51% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market revenue for PD1 Nonsmall cell lung cancer treatment was US$ 18.2 Billion in 2018 while exhibiting a CAGR of 5.7%. Pharmaceutical companies have begun to develop additional anti-PD-1/PD-L1 antibodies to overcome resistance and are devising further immunotherapy combinations which is creating space for market expansion. More than 20 anti-PD-1/PD-L1 antibodies have been approved or are currently in development. Numerous combination therapies are under development, and several combination therapies have provided positive results in randomized controlled trials which presents growth avenues for the market.
The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2020, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year.
Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for around 3 million deaths in 2020. This boosts the market growth. Thus, considering these factors and developments, FMI has estimated the market to gross a value of US$ 61 Billion with a CAGR of 8.51% by end of the forecast period.
New drug approvals to fuel market growth
The rising number of new drug approvals by regulatory authorities for the treatment of non-small cell lung cancer is anticipated to drive the growth of the market. For instance, in May 2019, Pfizer Inc., which is a USA-based multinational pharmaceutical and biotechnology corporation received the European Commission’s (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This development will aid in market growth.
Moreover, with the approval of Nivolumab, immune-checkpoint inhibitors (ICIs), mainly anti-programmed cell death-1 (PD-1) antibodies, have rapidly revolutionized cancer treatment which is anticipated to drive the market in the forecast period. The recommendation of combination therapy with an anti-PD-1/PD-L1 antibody and platinum-based chemotherapy as a first-line therapy for patients with advanced NSCLC without driver gene mutations will augment the growth of the PD1 Non-small cell lung cancer treatment market during the forecast period
Rising demand for oral drugs to augment product demand
Oral drugs are expected to boost the market growth. The segment is estimated to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Principal Consultant
Lack of skilled professionals restraining market growth
The dearth of trained professionals who are unaware of treatment methods for this disease may restrict the growth of the global PD1 non-small cell lung cancer treatment market during the forecast period.
High cost of treatment to hamper market expansion
The high cost of drugs is a major blockade for patients to adopt these drugs easily. Thus, presenting challenges for market expansion.
North America rules the market with the highest market share
This region is expected to dominate the market with a market share of 42% during the forecast period. The market in the USA was estimated at US$ 9.2 Billion in 2022. The growth is attributed due to increasing support from the U.S. Government for developing therapies and drugs to treat different types of cancer. The availability of state-of-the-art research facilities and access to advanced testing equipment helps with successful research, which is contributing to market growth.
Furthermore, high research and development activities, the launch of companion diagnostics by industry players, and massive healthcare spending are propelling the growth of the overall regional market to a large extent. ?The cost of treatment which includes chemotherapy, immunotherapy, targeted therapy, radiation, and in some cases, surgery, is vast, and the availability of significant reimbursement in the region is likely to augment market growth.
South Asia to witness the fastest growth in the forecast period
This region is expected to witness the fastest CAGR of 8% in the forecast period. The market in this region is projected to account for 25.5% of revenue by 2033. China is expected to grow at a CAGR of 13.7% with a market valuation to reach US$ 12.2 Billion by end of the forecast period. The growth in this region is attributable to the presence of a large patient population and the rise in research and development activities in the pharmaceutical sector.
Moreover, the presence of companies and growth in the purchasing power of countries like India and China will fuel product demand. Also, the rise in the adoption of therapies for cancer and the adoption of high-tech processing to improve training programs are driving growth in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for Targeted Cancer Therapies on the Rise
Targeted therapy is expected to dominate the market by reaching a valuation of US$ 31.7 Billion by end of the forecast period while exhibiting a CAGR of 10%. This segment is expected to continue this trend owing to distinct clinical benefits offered by this therapy such as minimal side effects along with the availability of a number of targeted therapeutics.
In addition, rise in the number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in up to 80% of cases. These factors will propel the segment’s growth in the upcoming years.
Hospital Pharmacies account for the Maximum Availability of key Drugs
This segment is expected to account for 52% market share while trailing at a CAGR of 12% during the forecast period. The dominance is due to an increase in the number of hospitalizations of patients suffering from PD1 Non-small cell lung cancer and the presence of skilled professionals within these settings.
The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Merck Co. & Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, AstraZeneca Plc, Pfizer Inc, Merck KGaA, Novartis AG, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Sanofi, and Agennix AG. Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 26.96 Billion |
| Market Value in 2033 | US$ 61 Billion |
| Growth Rate | CAGR of 8.51% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market witnessed a CAGR of 5.7% from 2018 to 2022.
The market is expected to reach US$ 31.7 billion through 2033.
The hospital pharmacies segment is estimated to register a growth rate of 12% until 2033.
North America’s market is expected to dominate with a market share of 42%.
The market is valued at US$ 26.96 billion in 2023.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Nivolumab 5.3.2. Pembrolizumab 5.3.3. Atezolizumab 5.3.4. Avelumab 5.3.5. Durvalumab 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Cancer Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Cancer Type, 2023 to 2033 6.3.1. Squamous Cell Carcinoma 6.3.2. Adenocarcinoma 6.3.3. Large-cell Carcinoma 6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By Treatment, 2018 to 2022 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Treatment, 2023 to 2033 7.3.1. Chemotherapy 7.3.2. Targeted Therapy 7.3.3. Immunotherapy 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022 8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Online Pharmacies 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The USA 10.2.1.2. Canada 10.2.2. By Drug Type 10.2.3. By Cancer Type 10.2.4. By Treatment 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Cancer Type 10.3.4. By Treatment 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Type 11.2.3. By Cancer Type 11.2.4. By Treatment 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Cancer Type 11.3.4. By Treatment 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. The United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Type 12.2.3. By Cancer Type 12.2.4. By Treatment 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Cancer Type 12.3.4. By Treatment 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Type 13.2.3. By Cancer Type 13.2.4. By Treatment 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Cancer Type 13.3.4. By Treatment 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Type 14.2.3. By Cancer Type 14.2.4. By Treatment 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Cancer Type 14.3.4. By Treatment 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Type 15.2.3. By Cancer Type 15.2.4. By Treatment 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Cancer Type 15.3.4. By Treatment 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Type 16.2.3. By Cancer Type 16.2.4. By Treatment 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Type 16.3.3. By Cancer Type 16.3.4. By Treatment 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. The USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Type 17.1.2.2. By Cancer Type 17.1.2.3. By Treatment 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Type 17.2.2.2. By Cancer Type 17.2.2.3. By Treatment 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Type 17.3.2.2. By Cancer Type 17.3.2.3. By Treatment 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Type 17.4.2.2. By Cancer Type 17.4.2.3. By Treatment 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Type 17.5.2.2. By Cancer Type 17.5.2.3. By Treatment 17.5.2.4. By Distribution Channel 17.6. U.K. 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Type 17.6.2.2. By Cancer Type 17.6.2.3. By Treatment 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Type 17.7.2.2. By Cancer Type 17.7.2.3. By Treatment 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Type 17.8.2.2. By Cancer Type 17.8.2.3. By Treatment 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Type 17.9.2.2. By Cancer Type 17.9.2.3. By Treatment 17.9.2.4. By Distribution Channel 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Type 17.10.2.2. By Cancer Type 17.10.2.3. By Treatment 17.10.2.4. By Distribution Channel 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Type 17.11.2.2. By Cancer Type 17.11.2.3. By Treatment 17.11.2.4. By Distribution Channel 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Type 17.12.2.2. By Cancer Type 17.12.2.3. By Treatment 17.12.2.4. By Distribution Channel 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Type 17.13.2.2. By Cancer Type 17.13.2.3. By Treatment 17.13.2.4. By Distribution Channel 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Type 17.14.2.2. By Cancer Type 17.14.2.3. By Treatment 17.14.2.4. By Distribution Channel 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Type 17.15.2.2. By Cancer Type 17.15.2.3. By Treatment 17.15.2.4. By Distribution Channel 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Type 17.16.2.2. By Cancer Type 17.16.2.3. By Treatment 17.16.2.4. By Distribution Channel 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Type 17.17.2.2. By Cancer Type 17.17.2.3. By Treatment 17.17.2.4. By Distribution Channel 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Type 17.18.2.2. By Cancer Type 17.18.2.3. By Treatment 17.18.2.4. By Distribution Channel 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Type 17.19.2.2. By Cancer Type 17.19.2.3. By Treatment 17.19.2.4. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Type 17.20.2.2. By Cancer Type 17.20.2.3. By Treatment 17.20.2.4. By Distribution Channel 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Type 17.21.2.2. By Cancer Type 17.21.2.3. By Treatment 17.21.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Type 18.3.3. By Cancer Type 18.3.4. By Treatment 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Merck Co. & Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. Bristol-Myers Squibb 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. F. Hoffmann-La Roche AG 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. AstraZeneca Plc. 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Pfizer Inc. 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Merck KGaA 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Novartis AG 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. GlaxoSmithKline plc. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Takeda Pharmaceutical Company Limited 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Eli Lilly and Company 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.11. Sanofi 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.12. Agennix AG 19.1.12.1. Overview 19.1.12.2. Product Portfolio 19.1.12.3. Profitability by Market Segments 19.1.12.4. Sales Footprint 19.1.12.5. Strategy Overview 19.1.12.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
PD1 Non-Small Cell Lung Cancer Treatment Market
